EuroBiotech: More Articles of Note


> Cassiopea posted more positive data on its pipeline. On Monday, the company reported interim data on clascoterone in androgenetic alopecia. Days later, Cassiopea added phase 2 genital wart data to its list of recent readouts. Release I More

> Takeda struck a deal to assess the feasibility of leon-nanodrugs’ MicroJet Reactor. Statement 

> Silence Therapeutics named David Horn Solomon as its CEO. Solomon ran Zealand Pharma from 2008 to 2015. Release

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.

> Poxel posted data from a phase 1b NASH trial. The French biotech will now move the candidate into phase 2a. Statement

> Adaptimmune received clearance for dose escalation in its MAGE-A10 pilot studies. Release